CI
NVCR icon

CX Institutional’s NovoCure NVCR Stock Holding History

CX Institutional’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-10
Closed -$1K – 917
2022
Q2 		$1K Buy
+10
New +$753 ﹤0.01% 1151
2019
Q3 		– Sell
-57
Closed -$4K – 907
2019
Q2 		$4K Buy
+57
New +$2.89K ﹤0.01% 660

Other funds holding NVCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

CX Institutional's NVCR Position: Q3 2022 in Review

CX Institutional sold out of NovoCure (NVCR) in Q3 2022, closing a stake of 10 shares — an estimated $1K sold.

CX Institutional first reported a position in NVCR in Q2 2019 and held it in 2 quarters. The position peaked at $4K in Q2 2019. 303 funds tracked by Wall St. Rank hold NVCR as of Q3 2022.

  • CX Institutional reported no remaining NovoCure position as of Q3 2022 after selling out during the quarter.
  • CX Institutional sold 10 NovoCure shares in Q3 2022, an estimated $1K.
  • CX Institutional first reported a position in NovoCure in Q2 2019 and held it in 2 quarters.
  • CX Institutional's NovoCure position peaked at $4K in Q2 2019.
  • 303 funds tracked by Wall St. Rank held NovoCure as of Q3 2022.

Based on CX Institutional's 13F filing for Q3 2022, filed 4 Nov 2022.